Interv Akut Kardiol. 2007;6(1):20-23

CARDIAC MARKERS AT THE BEGINNING OF THE THIRD MILLENIUM

Radek Pudil2, Miloš Tichý1, Jan Vojáček2,3
1 Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové
2 I. interní klinika Fakultní nemocnice v Hradci Králové
3 Kardiocentrum dospělých, oddělení invazivní kardiologie interní kliniky 2. LF UK a FN Motol, Praha

The purpose of this review is to provide an overview of essential clinical characteristics of several biomarkers that may have a potential clinical utility in diagnosing process and risk stratification in patients with acute coronary syndromes and heart failure. These biomarkers belong to those, which can detect myocardial ischemia and necrosis (troponin T and I, creatinkinase, ischemia-modified albumin, fatty acids binding protein, choline, glycogen phoshorylase isoenzyme BB, placental growth hormone, pregnancy-associated protein A, soluble CD40 ligand) and markers of myocardial function (natriuretic peptides).

Authors reveal essential summary of these parameters enriched with the possible use of these parameters in clinical practice and research.

Key words: biomarkers, myocardial necrosis, myocardial ischemia, troponincreatinkinase, ischemia-modified albumin, fatty acids binding protein, choline, glycogen phoshorylase isoenzyme BB, placental growth hormone, pregnancy-associated protein A, sCD40L, natriuretic peptides.

Keywords: biomarkers, myocardial necrosis, myocardial ischemia, troponincreatinkinase, ischemia-modified albumin, fatty acids binding protein, choline, glycogen phoshorylase isoenzyme BB, placental growth hormone, pregnancy-associated protein A, sCD40L, natriuretic peptides

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R, Tichý M, Vojáček J. CARDIAC MARKERS AT THE BEGINNING OF THE THIRD MILLENIUM. Interv Akut Kardiol. 2007;6(1):20-23.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Apple F, Wu A, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndromes. Clin Chem 2005;51:810-825. Go to original source... Go to PubMed...
    2. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: From retrospective detection to gold standard for acute myocardial infarction and more. Clin Chim Acta 2006;369:179-187. Go to original source... Go to PubMed...
    3. Antman E, Bassand JP, Klein W, Ohman M, Lopez Sendon JL, Rydén L, Simoons M, Tendera M. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. The Joint European Society of Cardiology/ American College of Cardiology Committee. JACC 2000;36:959-969. Go to original source... Go to PubMed...
    4. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809-1840. Go to original source... Go to PubMed...
    5. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al. Management of acute myocardial infarction inpatients presenting with ST-segment elevation The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66. Go to original source... Go to PubMed...
    6. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001;39:175-179. Go to original source... Go to PubMed...
    7. Friedecký B. Troponiny - hlavní biochemické ukazatele poškození myokardu. Konfrontace mezinárodních doporučení s reálnými možnostmi klinických laboratoří. Cor Vasa 2002;44:422-425.
    8. Engliš M. Super (ultra, high) senzitivní metody stanovení srdečních troponinů. Labor actuell 2006;3:22-23.
    9. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004;35:1-5. Go to original source...
    10. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003;49:581-585. Go to original source... Go to PubMed...
    11. Kleinfeld AM, Kleinfeld KJ, Adams JE. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002;39:312A. Go to original source...
    12. Kurien VA, Oliver MF. Serum-free fatty acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 1966;288:122-127. Go to original source... Go to PubMed...
    13. Kleinfeld AM, Prothro D, Brown D, Davis RC, Richierie GV, DeMaria A. Increases in serum unbound free fatty acid concentrations following coronary angioplasty. Am J Cardiol 1996;78:1350-1354. Go to original source... Go to PubMed...
    14. Jouven X, Charles MA, Desnos M, Ducimeti re P.Circulating Nonesterified Fatty Acid Level as a Predictive Risk Factor for Sudden Death in the Population. Circulation 2001;104: 756-761. Go to original source... Go to PubMed...
    15. Danne O, Möckel M, Lueders C, Mügge C, Zschunke GA, Lufft H, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003;91:1060-1067. Go to original source... Go to PubMed...
    16. Gomez-Munoz A, Martens JS, Steinbrecher UP. Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 2000;20:135-143. Go to original source... Go to PubMed...
    17. Williger BT, Ho WT, Exton JH. Phospholipase D mediates matrix metalloproteinase-9 secretion in phorbol ester stimulated human fibrosarcoma cells. J Biol Chem 1999;274:735-738. Go to original source... Go to PubMed...
    18. Khosravi J, Diamandi A, Krishna RG, Bodani U, Mistry J, Khaja N. Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem 2002;35:531-538. Go to original source... Go to PubMed...
    19. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, et al. Circulating pregnancyassociated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108:1924-1926. Go to original source... Go to PubMed...
    20. Heeschen C, Fichtlscherer S, Hamm CW. Pregnancy-associated plasma protein-A (PAPPA) plasma level independently predict outcome in troponin negative patients with acute coronary syndrome. Circulation 2003;108 (Suppl IV):470.
    21. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291:435-441. Go to original source... Go to PubMed...
    22. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation 1999;100:614-620. Go to original source... Go to PubMed...
    23. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108:2776-2782. Go to original source... Go to PubMed...
    24. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268. Go to original source... Go to PubMed...
    25. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111. Go to original source... Go to PubMed...
    26. Ridker, PM, Cook N. Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation, Apr 2004;109:1955-1959. Go to original source... Go to PubMed...
    27. Koenig W, Sund M, Frohlich M, et al. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol. 2003;158:357-364. Go to original source... Go to PubMed...
    28. Morrow DA, de Lemos JA, Sabatine M, Wiviott S, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial. Circulation, Jul 2006;114:281-288. Go to original source... Go to PubMed...
    29. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation, Aug 2004;110:1061-1068. Go to original source... Go to PubMed...
    30. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, Tate J, et al. Quality specifications for B- type natriuretic peptide assays. Clin Chem 2005;51:486-493. Go to original source... Go to PubMed...
    31. Denus S, Pharand C, Williamson D. Brain Natriuretic Peptide in the Management of Heart Failure. Chest 2004;125:652-668. Go to original source... Go to PubMed...
    32. Tjeerdsma G, de Boer RA, Boomsma F, van den Berg MP, Pinto YM, van Veldhuisen DJ. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2002;86:143-149. Go to original source... Go to PubMed...
    33. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The Nterminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954. Go to original source... Go to PubMed...
    34. Cappellin E, Gatti R, Spinella P, De Palo CB, Woloszczuk W, Maragno I, De Palo EF. Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta. 2001;310:49-52. Go to original source... Go to PubMed...
    35. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735-1743. Go to original source... Go to PubMed...
    36. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha-Goncalves F, Ferreira A. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol. 2004;93:45-48. Go to original source... Go to PubMed...
    37. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN; For the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292-299. Go to original source... Go to PubMed...
    38. Daly C, Fox K, Henein M. Natriuretic peptides in the diagnosis of heart disease-first amongst equals? Int J Cardiol. 2002;84:107-113. Go to original source... Go to PubMed...
    39. Hall C. Essential biochemistry and pathophysiology of NT-pro BNP.Eur J Heart Failure 2004;6:257-260. Go to original source... Go to PubMed...
    40. Clerico A, Emdin M. Diagnostic and prognostic relevance of measurement of cardiac natriuretic peptides: A review. Clin Chem 2005;50:33-50. Go to original source... Go to PubMed...
    41. Pudil R, Tichy M, Blaha V, Praus R, Vojacek J. NT-proBNP correlates not only with ejection fraction, but also with inferior vena cava diameter in patients with acute heart failure. Clin Chim Acta, In press.
    42. Tichý M, Gregor J. Přehled biochemických markerů poškození myokardu. Klin Biochem Metab 2002;10 (BCB 31), no.3:176-179.
    43. Tichý M, Friedecký B, Palička V, Horáček J, Jebavý L, Pudil R. Současné názory na stanovení a klinické využití kardiomarkerů. Klin Biochem Metab 2005; 13(34): 98-102.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.